India & Oman Pharmaceutical Industry Market, by Drug (Generic and Patented (Branded)), by Type (Prescription Drugs and Over the Counter Drugs), by Drug Class (Analgesics, Anesthetics, Antibacterials, Antidepressants, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Anticonvulsants, Antivirals, Anticoagulants, ACE inhibitors, Hormonal agents, Insulin, Contraceptives, Diuretics, Vaccines, and Others), by Application (Cardiovascular (Ischemic Heart Disease and Others), Hypertension, Musculoskeletal, Oncology, Anti-infective, Cirrhosis, Metabolic Disorder (Diabetes and Others), Weight Management, Central Nervous System, Genito-urinary, Kidney Disease, Gastrointestinal, Respiratory, Hematology, Dermatology, Ophthalmology, and Others (Nutraceutical, Dentals, and Gynecology)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and by Country (India and Oman), is estimated to be valued at US$ 47,179.5 Million in 2021 and is expected to exhibit a CAGR of 12.7% over the forecast period (2021-2030), as highlighted in a new report published by Coherent Market Insights.
The rising investments by the government bodies in Indian and Oman pharmaceutical industries is expected to propel growth of the market over the forecast period. For instance, in January 2021, the Central Government of India, announced that India will launch three bulk drug parks (manufacturing units) in India to reduce the dependency of the India on China for raw materials used in pharmaceutical industries. The drug parks will be set up of INR 14,300 crore (US$ 192.55 Mn) and the ministry of health, India also announced the launch of additional four units of bulk drug parks (manufacturing units) in India by 2025. Whereas, in 2014, the government of Oman released a long-term programme for the domestic healthcare sector, Health Vision 2050, which aimed at creating a well-organized, efficient and responsive health system within the country.
India & Oman Pharmaceutical Industry Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has affected various industries globally. The players operating in the India & Oman pharmaceutical industry market are facing major challenges on various fronts due to the COVID-19 pandemic. Supply chain and manufacturing activities in India and Oman have been disrupted due to nationwide lockdown; while Indian states such as Maharashtra, Gujarat, Rajasthan, and others are facing problems with regards to transportation of pharmaceutical products due to partial lockdowns and termination of interstate transport in India. Government of different countries including Oman has helped India in the fight against the COVID-19 by providing various important medical assistive products. For instance, in May 2021, Government of Oman dispatched special medical assistance for India’s fight against COVID-19 and the special medical assistance included medical supplies of ventilators, SPO2 monitors, and medicines gifted by the Sultanate of Oman. The government initiative from both the government of India & Oman are planning the vaccination drives for reducing the spread of COVID-19 infections in India and Oman.
Browse 89 Market Data Tables and 64 Figures spread through 465 Pages and in-depth TOC on “India & Oman Pharmaceutical Industry Market”- Forecast to 2030, India & Oman Pharmaceutical Industry Market, by Drug (Generic and Patented (Branded)), by Type (Prescription Drugs and Over the Counter Drugs), by Drug Class (Analgesics, Anesthetics, Antibacterials, Antidepressants, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Anticonvulsants, Antivirals, Anticoagulants, ACE inhibitors, Hormonal agents, Insulin, Contraceptives, Diuretics, Vaccines, and Others), by Application (Cardiovascular (Ischemic Heart Disease and Others), Hypertension, Musculoskeletal, Oncology, Anti-infective, Cirrhosis, Metabolic Disorder (Diabetes and Others), Weight Management, Central Nervous System, Genito-urinary, Kidney Disease, Gastrointestinal, Respiratory, Hematology, Dermatology, Ophthalmology, and Others (Nutraceutical, Dentals, and Gynecology)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and by Country (India and Oman).
To know the latest trends and insights prevalent in this market, click the link below:
The key players operating in the market are focusing on increasing number of the product launches in the Indian pharmaceutical industry to drive growth of the India pharmaceutical industry market over the forecast period. For instance, in February 2021, Natco Pharma, an India-based pharmaceutical company announced the launch of Brivaracetam for the treatment of epilepsy in India.
Key Takeaways of the India & Oman Pharmaceutical Industry Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients